Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib versus investigator-choice covalent BTK inhibitor in previously treated mantle cell lymphoma
NL-OMON60799Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirtobrutinib in mantle cell lymphoma (MCL), sponsored by Loxo Oncology. Started Mar 2021; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON60799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60799.